This sounds promising, can some of our science people weigh in a bit more on whether this could be beneficial in conjunction with Rapamycin?
2 Likes
Evidence in favor of Urolithin A building, but I don’t see a reason to combine with Rapamycin.
5 Likes
Naive CD8 expression was also a primary endpoint, so claiming that marker is pivoting away from the primary endpoint isn’t really true either.
It’s definitely problematic if they don’t emphasize the other primary endpoint not being met, but also par for the course in this space.
3 Likes
But aren’t the only studies the ones paid for by Mitopure?
1 Like
I believe there have been NIH studies.
Based on my research, there is one NIH trial currently being conducted but there are no results from it yet. All the other trials were “sponsored, run, or funded by Amazentis (the company that makes Mitopure/ Timeline)”.
1 Like
agree with what mentioned here. So far (and this is valid as well for “fatty 15” or “C15”) if the number of studies is having any conflict of interest statement I’ll simply disregard it. In this specific case “Effect of the mitophagy inducer urolithin A on age-related immune decline: a randomized, placebo-controlled trial - PubMed” Conflict of interest statement
Competing interests: A.S., D. D’Amico and J.F. are employees, and C.R. is president and delegate of the board of Amazentis SA, which funded this clinical study and provided the investigational product (Mitopure). F.R.G. has received consulting fees from Amazentis. D. Denk has received travel compensation from Amazentis and AbbVie. There are restrictions to the commercial use of SCENITH due to a pending patent application (PCT/EP2020/WO2020212362A1 to R.J.A.). The remaining authors declare no competing interests related to this study.